Biocon Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Biocon will hold a meeting of the Board of Directors of the Company on 7 May 2026.

Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 362.1, up 0.85% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.77% on the day, quoting at 24552.55. The Sensex is at 79171.6, up 0.83%. Biocon Ltd has slipped around 1.38% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 1.88% in last one month and is currently quoting at 22456.75, up 0.05% on the day. The volume in the stock stood at 15.64 lakh shares today, compared to the daily average of 40.6 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 361.85, up 0.88% on the day. Biocon Ltd is up 8.48% in last one year as compared to a 1.59% jump in NIFTY and a 4.81% jump in the Nifty Pharma index.

The PE of the stock is 298.75 based on TTM earnings ending December 25.

The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, demonstrating that BOSAYA and VEVZUO are highly similar to PROLIA and XGEVA, respectively, with no clinically meaningful differences in quality, safety, or efficacy.

Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.

Shreehas Tambe, CEO & managing director, Biocon, said: ?Health Canada?s approval of BOSAYA and VEVZUO marks another important milestone for Biocon as we continue to expand access to high-quality biosimilars in key global markets.

This approval reflects our strong scientific and regulatory capabilities and reinforces our commitment to patients living with osteoporosis and cancer-related bone conditions, while further strengthening our portfolio of affordable biologic therapies across immunology and oncology.

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

The company's consolidated net profit surged to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4,123 crore in Q3 FY26 as compared with Q3 FY25.

Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Bosaya? (denosumab), a biosimilar to Prolia?, and Vezuo? (denosumab), a biosimilar to Xgeva?, on 03 April 2026. Both biosimilars were approved in the most common presentations: BOSAYA, as a 60 mg/mL injection for subcutaneous use in a prefilled syringe; and VEVZUO, as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial.

Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.

Shreehas Tambe, CEO & Managing Director, Biocon, said, ?Health Canada's approval of BOSAYA and VEVZUO marks another important milestone for Biocon as we continue to expand access to high-quality biosimilars in key global markets. This approval reflects our strong scientific and regulatory capabilities and reinforces our commitment to patients living with osteoporosis and cancer-related bone conditions, while further strengthening our portfolio of affordable biologic therapies across immunology and oncology.?